Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report.
Nail PaksoySelcuk ErdemMert KaracaNaziye AkMetin PehlivanInci K YirginYasemin OzlukFeza EkizDeniz TuralMeltem EkenelFaruk OzcanMert BasaranPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
During surveillance, rapid progression is noted under consecutive immunotherapy which was unexpected. Thus, there is a need for more standardized treatment protocols and invention of new agents for management of TFE3 (+) renal cell carcinoma.